BMS pens immune checkpoint deal with Five Prime Therapeutics; FPA008 agreement replaced
Executive Summary
About a month after raising $41mm publicly, protein drug discovery firm Five Prime Therapeutics Inc. is getting more cash via a new deal with Bristol-Myers Squibb Co. in the cancer immunotherapeutics area. BMS will have exclusive worldwide development and marketing rights to resulting products.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Trial Collaborations
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice